Mini-review on Inhibitors of Human Tyrosinase

Jyoti Srivastava; Joyabrata Mal; Manju Verma; Rupika Sinha

doi:10.2991/978-94-6463-020-6_10

<Previous Article In Volume

Next Article In Volume>

Mini-review on Inhibitors of Human Tyrosinase

Authors

Jyoti Srivastava¹, Joyabrata Mal¹, Manju Verma², Rupika Sinha¹^{, *}

¹Department of Biotechnology, Motilal Nehra National Institute of Technology Allahabad, Prayagraj, Uttar Pradesh, 211004, India

²Department of Chemical Engineering, Motilal Nehra National Institute of Technology Allahabad, Prayagraj, Uttar Pradesh, 211004, India

^*Corresponding author. Email: rupika@mnnit.ac.in

Corresponding Author

Rupika Sinha

Available Online 14 December 2022.

DOI: 10.2991/978-94-6463-020-6_10 How to use a DOI?
Keywords: Human tyrosinase; Mushroom tyrosinase; Tyrosinase inhibitor; Hyperpigmentation; Melanin
Abstract: Melanin is a major pigment of human skin that protects the skin from harmful ultraviolet radiation, DNA damage and oxidative stress. However, the excess accumulation of melanin may lead to various hyperpigmentation-related diseases. Tyrosinase is a copper containing enzyme that regulates the rate-limiting step of melanin synthesis. So, inhibiting tyrosinase is the crucial target for researchers for the treatment of hyperpigmentation. Unfortunately, almost all the literature is based on mushroom tyrosinase (mTYR) for their application on humans as pure human tyrosinase (hTYR) is difficult to isolate. Since presently used tyrosinase inhibitors are developed using mushroom tyrosinase, they are insufficient to match the affinity, selectivity and efficacy required to target the human tyrosinase. Therefore, there is an urgent need for identifying a selective tyrosinase inhibitor that matches the selectivity and safety standards of human tyrosinase. This mini-review is focused on the tyrosinase inhibitors developed and evaluated using human tyrosinase.
Copyright: © 2023 The Author(s)
Open Access: Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume

Next Article In Volume>

Volume Title: Proceedings of the conference BioSangam 2022: Emerging trends in Biotechnology (BIOSANGAM 2022)
Series: Advances in Biological Sciences Research
Publication Date: 14 December 2022
ISBN: 10.2991/978-94-6463-020-6_10
ISSN: 2468-5747
DOI: 10.2991/978-94-6463-020-6_10 How to use a DOI?
Open Access: Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

ris enw bib

TY  - CONF
AU  - Jyoti Srivastava
AU  - Joyabrata Mal
AU  - Manju Verma
AU  - Rupika Sinha
PY  - 2022
DA  - 2022/12/14
TI  - Mini-review on Inhibitors of Human Tyrosinase
BT  - Proceedings of the conference BioSangam 2022: Emerging trends in Biotechnology (BIOSANGAM 2022)
PB  - Atlantis Press
SP  - 96
EP  - 105
SN  - 2468-5747
UR  - https://doi.org/10.2991/978-94-6463-020-6_10
DO  - 10.2991/978-94-6463-020-6_10
ID  - Srivastava2022
ER  -

download .riscopy to clipboard